Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?
Cells · 2024
DOI: 10.3390/cells13181558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Silvia Brugiapaglia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44bis, 10126 Turin, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Progetti di Rilevante Interesse Nazionale-PRIN, European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and strengthening of biomedical research in the NHS, European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS.
Abstract (Originalsprache)
Pancreatic adenocarcinoma (PDA) represents the fourth leading cause of cancer-related mortality in the USA. Only 20% of patients present surgically resectable and potentially curable tumors at diagnosis, while 80% are destined for poor survival and palliative chemotherapy. Accordingly, the advancement of innovative and effective therapeutic strategies represents a pivotal medical imperative. It has been demonstrated that targeting the immune system represents an effective approach against several solid tumors. The immunotherapy approach encompasses a range of strategies, including the administration of antibodies targeting checkpoint molecules (immune checkpoint inhibitors, ICIs) to disrupt tumor suppression mechanisms and active immunization approaches that aim to stimulate the host’s immune system. While vaccines have proved effective against infectious agents, vaccines for cancer remain an unfulfilled promise. Vaccine-based therapy targeting tumor antigens has the potential to be a highly effective strategy for initiating and maintaining T cell recognition, enhancing the immune response, and ultimately promoting cancer treatment success. In this review, we examined the most recent clinical trials that employed diverse vaccine types to stimulate PDA patients’ immune systems, either independently or in combination with chemotherapy, radiotherapy, ICIs, and monoclonal antibodies with the aim of ameliorating PDA patients’ quality of life and extend their survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44bis, 10126 Turin, Italy.
- School of Advanced Defence Studies, Defence Research & Analysis Institute, Piazza della Rovere 83, 00165 Rome, Italy.
ORCID-Profile: Ferdinando Spagnolo, Claudia Curcio
Förderung
- Progetti di Rilevante Interesse Nazionale-PRIN
- European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
- European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
Zitieren
APA
Brugiapaglia, S., Spagnolo, F., Intonti, S., Novelli, F., & Curcio, C. (2024). Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?. Cells. https://doi.org/10.3390/cells13181558
Vancouver
Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C. Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?. Cells. 2024. doi:10.3390/cells13181558
BibTeX
@article{Brugiapaglia2024,
author = {Brugiapaglia, Silvia and Spagnolo, Ferdinando and Intonti, Simona and Novelli, Francesco and Curcio, Claudia},
title = {Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13181558}
}
EUVIMED